muramidase and Pain

This observational clinical study was composed of two substudies: a non-comparative one (n = 166), testing only lysozyme-based compounds (LBCs), and a comparative substudy (n = 275), testing both LBCs and bicarbonate-based local compounds (BBCs) on the healing of oral mucositis during radio- or chemotherapy. The density of ulcerations has decreased significantly after the treatment with lysozyme in both substudies. The density of ulcerations in the radiotherapy group was lower in patients treated with LBCs compared to patients treated with BBCs (p < 0.001). In the chemotherapy group, reduction of ulceration density was similar with both LBCs and BBCs. The LBCs reduced pain intensity during the intake of solid food and speech more than BBCs in both patient cohorts (p < 0.05). In the radiotherapy cohort, pain intensity when consuming liquid foods was reduced more with LBCs than with BBCs (p < 0.05). No adverse events were recorded. This study demonstrates the advantages of treating oral mucositis during radiotherapy or chemo-therapy with LBCs.

Topics: Antineoplastic Agents; Dermatologic Agents; Female; Humans; Male; Middle Aged; Muramidase; Pain; Radiotherapy; Stomatitis

The objective of the present study was to estimate the efficacy of laripront intended for the treatment of inflammatory diseases of the laryngopharynx in the children. Available for the observation were 50 patients aged between 4 and 14 years suffering from the following ENT pathologies: adenoiditis, lacunar tonsillitis, acute laryngitis, chronic tonsillitis, oropharyngeal candidiasis, chronic hypertrophic pharyngitis, atrophic pharyngolaryngitis after the chemical burn of the mouse cavity and laryngopharynx or in the case of gastroesophageal reflux disease. All the patients enjoyed the positive outcome of the treatment that was especially efficacions in the patients with acute pathologies. No adverse effects of the treatment were documented.

Topics: Acute Disease; Adolescent; Anti-Infective Agents, Local; Child; Child, Preschool; Chronic Disease; Dequalinium; Drug Combinations; Drug Monitoring; Drug Synergism; Female; Humans; Hypopharynx; Male; Muramidase; Pain; Respiratory Tract Infections; Tablets; Treatment Outcome

Pathophysiologic differences in neural responses to hypertonic saline (HTS) were investigated in subjects with acute sinusitis (n = 25), subjects with chronic fatigue syndrome (CFS) with nonallergic rhinitis (n = 14), subjects with active allergic rhinitis (AR; n = 17), and normal (n = 20) subjects. Increasing strengths of HTS were sprayed into their nostrils at 5-minute intervals. Sensations of nasal pain, blockage, and drip increased with concentration and were significantly elevated above normal. These parallels suggested activation of similar subsets of afferent neurons. Urea and lysozyme secretion were dose dependent in all groups, suggesting that serous cell exocytosis was one source of urea after neural stimulation. Only AR and normal groups had mucin dose responses and correlations between symptoms and lysozyme secretion (R(2) = 0.12-0.23). The lysozyme dose responses may represent axon responses in these groups. The neurogenic stimulus did not alter albumin (vascular) exudation in any group. Albumin and mucin concentrations were correlated in sinusitis, suggesting that nonneurogenic factors predominated in sinusitis mucous hypersecretion. CFS had neural hypersensitivity (pain) but reduced serous cell secretion. HTS nasal provocations identified significant, unique patterns of neural and mucosal dysregulation in each rhinosinusitis syndrome.

Topics: Acute Disease; Administration, Intranasal; Adult; Albumins; Dose-Response Relationship, Drug; Fatigue Syndrome, Chronic; Female; Humans; Male; Middle Aged; Mucins; Mucus; Muramidase; Nasal Lavage Fluid; Nasal Mucosa; Nasal Provocation Tests; Neurons, Afferent; Pain; Rhinitis; Saline Solution, Hypertonic; Sinusitis; Urea

Pharmacological and pharmacokinetic characteristics of the non-ionic monomeric X-ray contrast agent iopromide (Ultravist, CAS 73334-07-3) were evaluated in preclinical studies. The scope of investigations included in vitro tests such as the determination of protein binding, the inhibition of complement, lysozyme, urokinase, platelet aggregation, the release of histamine, the influence on thromboplastin time. In vivo studies included bleeding time in rat, neural tolerance after intracisternal injection or administration into the carotid artery. Pharmacokinetic studies were performed in rats and dogs. Iopromide could be shown to be well tolerated in all the tests and species. Its pharmacokinetics was in agreement with the characteristics of an extracellular contrast agent with rapid renal elimination.

Topics: Animals; Bleeding Time; Complement Activation; Contrast Media; Dogs; Erythrocytes; Hemolysis; Histamine Release; Humans; In Vitro Techniques; Iohexol; Muramidase; Pain; Partial Thromboplastin Time; Platelet Aggregation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Urokinase-Type Plasminogen Activator

Hen egg white lysozyme (Fleming's lysozyme) was tested for antinociceptive activity in rats against foot hyperalgesia provoked by a subplantar injection of a number of irritants: arachidonic acid, brewer's yeast, carrageenan, kaolin, mepartricin and rabbit anti-rat serum (Randall-Selitto method). The compound was active when given p.o., i.m. or i.v. (100-200-400 mg/kg) as well as when injected locally in the foot pad concurrently with the irritant (1-2-4 mg/rat). Lysozyme decreased the sensitivity of the inflamed paw to the nociceptive stimulation, left unmodified the sensitivity of the normal paw and did not reduce the oedema of the inflamed paw. It differed in its activity from steroidal and non-steroidal anti-inflammatory drugs and from central analgesics that were used as standard reference drugs. Its activity was not shared by hen egg white and ovalbumin. Contrary to dextran, lysozyme i.p. did not induce anaphylactoid reactions. Lysozyme did not provoke tolerance and did not interfere with the antinociceptive activity of morphine. The results are in agreement with clinical data published years ago. Lysozyme was claimed to be an active agent against herpes zoster and cancer pain.

Topics: Analgesics; Animals; Arachidonic Acids; Chickens; Dextrans; Drug Evaluation, Preclinical; Egg White; Male; Morphine; Muramidase; Ovalbumin; Pain; Rats

Topics: Abdomen; Esterases; Hepatomegaly; Humans; Kidney Diseases; Leukemia, Monocytic, Acute; Monocytes; Muramidase; Pain; Splenomegaly

Topics: Humans; Muramidase; Neoplasms; Pain; Toxicology

Topics: Dermatologic Agents; Muramidase; Neoplasms; Pain; Virus Diseases

Topics: Antiviral Agents; Humans; Muramidase; Neoplasms; Pain

Topics: Anti-Infective Agents, Local; Dermatologic Agents; Muramidase; Neoplasms; Pain